Información de la revista
Vol. 2. Núm. 2.
Páginas 78-89 (Marzo - Abril 2006)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 2. Núm. 2.
Páginas 78-89 (Marzo - Abril 2006)
Artículo especial
Acceso a texto completo
Guías y recomendaciones del Colegio Mexicano de Reumatología para el uso de agentes biológicos en enfermos reumáticos
Visitas
9906
Comité Mexicano del Consenso de Biológicos. Colegio Mexicano de Reumatología 1
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S.W. Baumgartner, R.M. Fleischmann, L.W. Moreland, M.H. Schiff, J. Markenson, J.B. Whitmore.
Etanercept (enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: Improvement in disability.
J Rheumatol, 31 (2004), pp. 1532-1537
[2.]
B. Blumenauer, M. Judd, A. Cranney, A. Burls, D. Coyle, M. Hochberg, et al.
Etanercept for the treatment of rheumatoid arthritis.
Cochrane Database Syst Rev, (2003),
[3.]
M.C. Genovese, J.M. Bathon, R.M. Fleischmann, L.W. Moreland, R.W. Martin, J.B. Whitmore, et al.
Long-term safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.
J Rheumatol, 32 (2005), pp. 1232-1242
[4.]
E.C. Keystone, M.H. Schiff, J.M. Kremer, S. Kafka, M. Lovy, T. DeVries, et al.
Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, doubleblind, placebo-controlled trial.
Arthritis Rheum, 50 (2004), pp. 353-363
[5.]
L. Klareskog, D. Van der Heijde, J.P. De Jager, A. Gough, J. Kalden, M. Malaise, et al.
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial.
[6.]
J.M. Kremer, M.E. Weinblatt, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, C.G. Jackson, et al.
Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: Continued observations.
Arthritis Rheum, 48 (2003), pp. 1493-1499
[7.]
L.W. Moreland, S.B. Cohen, S.W. Baumgartner, E.A. Tindall, K. Bulpitt, R. Martin, et al.
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.
J Rheumatol, 28 (2001), pp. 1238-1244
[8.]
L.W. Moreland, M.H. Schiff, S.W. Baumgartner, E.A. Tindall, R.M. Fleischmann, K.J. Bulpitt, et al.
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
Ann Intern Med, 130 (1999), pp. 478-486
[9.]
M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, R.I. Fox, et al.
A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
N Engl J Med, 340 (1999), pp. 253-259
[10.]
F.C. Breedveld, P. Emery, E. Keystone, K. Patel, D.E. Furst, J.R. Kalden, et al.
Infliximab in active early rheumatoid arthritis.
Ann Rheum Dis, 63 (2004), pp. 149-155
[11.]
R.M. Fleischmann, S.B. Cohen, L.W. Moreland, M. Schiff, P.J. Mease, D.B. Smith, et al.
Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: The infliximab rheumatoid arthritis methotrexate tapering (iRAMT) trial.
Curr Med Res Opin, 21 (2005), pp. 1181-1190
[12.]
P.E. Lipsky, D.M. Van der Heijde, E.W. St. Clair, D.E. Furst, F.C. Breedveld, J.R. Kalden, et al.
Infliximab and methotrexate in the treatment of rheumatoid arthritis. anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group.
N Engl J Med, 343 (2000), pp. 1594-1602
[13.]
R. Maini, E.W. St. Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, et al.
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT study group.
Lancet, 354 (1999), pp. 1932-1939
[14.]
R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Furst, M.H. Weisman, et al.
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
Arthritis Rheum, 50 (2004), pp. 1051-1065
[15.]
J.S. Smolen, C. Han, M. Bala, R.N. Maini, J.R. Kalden, D. Van der Heijde, et al.
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Arthritis Rheum, 52 (2005), pp. 1020-1030
[16.]
E.W. St. Clair, D.M. Van der Heijde, J.S. Smolen, R.N. Maini, J.M. Bathon, P. Emery, et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial.
Arthritis Rheum, 50 (2004), pp. 3432-3443
[17.]
D.E. Furst, M.H. Schiff, R.M. Fleischmann, V. Strand, C.A. Birbara, D. Compagnone, et al.
Adalimumab, a fully human anti tumor necrosis factoralpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (safety trial of adalimumab in rheumatoid arthritis).
J Rheumatol, 30 (2003), pp. 2563-2571
[18.]
L.B. Van de Putte, C. Atkins, M. Malaise, J. Sany, A.S. Russell, P.L. Van Riel, et al.
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
Ann Rheum Dis, 63 (2004), pp. 508-516
[19.]
L.B. Van de Putte, R. Rau, F.C. Breedveld, J.R. Kalden, M.G. Malaise, P.L. Van Riel, et al.
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: A 12 week, phase II study.
Ann Rheum Dis, 62 (2003), pp. 1168-1177
[20.]
E.C. Keystone, A.F. Kavanaugh, J.T. Sharp, H. Tannenbaum, Y. Hua, L.S. Teoh, et al.
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial.
Arthritis Rheum, 50 (2004), pp. 1400-1411
[21.]
M.E. Weinblatt, E.C. Keystone, D.E. Furst, A.F. Kavanaugh, E.K. Chartash, O.G. Segurado.
Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study.
Ann Rheum Dis, 16 (2005),
[22.]
M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, C.A. Birbara, et al.
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial.
Arthritis Rheum, 48 (2003), pp. 35-45
[23.]
J. Brandt, H. Haibel, D. Cornely, W. Golder, J. González, J. Reddig, et al.
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
[24.]
F. Van den Bosch, E. Kruithof, D. Baeten, F. De Keyser, H. Mielants, E.M. Veys.
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study.
Ann Rheum Dis, 59 (2000), pp. 428-433
[25.]
H. Marzo-Ortega, D. McGonagle, P. O’Connor, P. Emery.
Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study.
[26.]
J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, W. Golder, et al.
Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial.
Lancet, 359 (2002), pp. 1187-1193
[27.]
M. Breban, E. Vignon, P. Claudepierre, V. Devauchelle, D. Wendling, E. Lespessailles, et al.
Efficacy of infliximab in refractory ankylosing spondylitis: Results of a six-month open-label study.
Rheumatology (Oxford), 41 (2002), pp. 1280-1285
[28.]
J.D. Gorman, K.E. Sack, J.C. Davis Jr.
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
N Engl J Med, 346 (2002), pp. 1349-1356
[29.]
J. Braun, X. Baraliakos, W. Golder, J. Brandt, M. Rudwaleit, J. Listing, et al.
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: Evaluation of a new scoring system.
Arthritis Rheum, 48 (2003), pp. 1126-1136
[30.]
J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, G. Burmester, et al.
Longterm efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial.
Arthritis Rheum, 48 (2003), pp. 2224-2233
[31.]
E. Collantes-Estévez, M.C. Muñoz-Villanueva, J.D. Cañete-Crespillo, R. Sanmartí-Sala, J. Gratacós-Masmitjà, P. Zarco-Montejo, et al.
Infliximab in refractory spondyloarthropathies: A multicentre 38 week open study.
Ann Rheum Dis, 62 (2003), pp. 1239-1240
[32.]
J.C. Davis Jr, D. Van der Heijde, J. Braun, M. Dougados, J. Cush, D.O. Clegg, et al.
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial.
Arthritis Rheum, 48 (2003), pp. 3230-3236
[33.]
J. Davis Jr, A. Webb, S. Lund, K. Sack.
Results from an open-label extension study of etanercept in ankylosing spondylitis.
Arthritis Rheum, 51 (2004), pp. 302-304
[34.]
J.C. Davis Jr, D.M. Van der Heijde, J. Braun, M. Dougados, J. Cush, D. Clegg, et al.
Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
Ann Rheum Dis, 26 (2005),
[35.]
S.M. Tse, R. Burgos-Vargas, R.M. Laxer.
Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
Arthritis Rheum, 52 (2005), pp. 2103-2108
[36.]
D. Van der Heijde, B. Dijkmans, P. Geusens, J. Sieper, K. DeWoody, P. Williamson, et al.
Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT).
Arthritis Rheum, 52 (2005), pp. 582-591
[37.]
A. Calin, B.A. Dijkmans, P. Emery, M. Hakala, J. Kalden, M. Leirisalo-Repo, et al.
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Ann Rheum Dis, 63 (2004), pp. 1594-1600
[38.]
B. Yazdani-Biuki, K. Wohlfahrt, A. Mulabecirovic, T. Mueller, J. Hermann, W.B. Graninger, et al.
Long term treatment of psoriatic arthritis with infliximab.
Ann Rheum Dis, 63 (2004), pp. 1531-1532
[39.]
C. Salvarani, F. Cantini, I. Olivieri, P. Macchioni, A. Padula, L. Niccoli, et al.
Efficacy of infliximab in resistant psoriatic arthritis.
Arthritis Rheum, 49 (2003), pp. 541-545
[40.]
F. Rinaldi, G. Provenzano, A. Termini, M. Spinello, F. La Seta.
Long term infliximab treatment for severe psoriatic arthritis: Evidence of sustained clinical and radiographic response.
Ann Rheum Dis, 64 (2005), pp. 1375-1376
[41.]
P.J. Mease, A.J. Kivitz, F.X. Burch, E.L. Siegel, S.B. Cohen, P. Ory, et al.
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression.
Arthritis Rheum, 50 (2004), pp. 2264-2272
[42.]
A. Kavanaugh, C. Antoni, G.G. Krueger, S. Yan, M. Bala, L.T. Dooley, et al.
Infliximab improves health-related quality of life and physical function in patients with psoriatic arthritis.
Ann Rheum Dis, (2005),
[43.]
P.J. Mease, D.D. Gladman, C.T. Ritchlin, E.M. Ruderman, S.D. Steinfeld, E.H. Choy, et al.
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial.
Arthritis Rheum, 52 (2005), pp. 3279-3289
[44.]
P.J. Mease, B.S. Goffe, J. Metz, A. Van der Stoep, B. Finck, D.J. Burge.
Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial.
[45.]
C. Antoni, C. Dechant, P.D. Hanns-Martin Lorenz, J. Wendler, A. Ogilvie, M. Lueftl, et al.
Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation.
Arthritis Rheum, 47 (2002), pp. 506-512
[46.]
C. Antoni, G.G. Krueger, K. De Vlam, C. Birbara, A. Beutler, C. Guzzo, et al.
Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial.
Ann Rheum Dis, 64 (2005), pp. 1150-1157
[47.]
C.E. Antoni, A. Kavanaugh, B. Kirkham, Z. Tutuncu, G.R. Burmester, U. Schneider, et al.
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Arthritis Rheum, 52 (2005), pp. 1227-1236
[48.]
K. De Vlam, R.J. Lories.
Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: A 26-week observational study.
Rheumatology (Oxford), (2005),
[49.]
M. Feletar, J.E. Brockbank, C.T. Schentag, V. Lapp, D.D. Gladman.
Treatment of refractory psoriatic arthritis with infliximab: A 12 month observational study of 16 patients.
Ann Rheum Dis, 63 (2004), pp. 156-161
[50.]
D.J. Lovell, E.H. Giannini, A. Reiff, G.D. Cawkwell, E.D. Silverman, J.J. Nocton, Etanercept in children with polyarticular juvenile rheumatoid arthritis. pediatric rheumatology collaborative study group, et al.
N Engl J Med, 342 (2000), pp. 763-769
[51.]
D.A. Kietz, P.H. Pepmueller, T.L. Moore.
Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis.
J Rheumatol, 28 (2001), pp. 360-362
[52.]
A. Martini.
Etanercept improves active polyarticular juvenile rheumatoid arthritis.
Clin Exp Rheumatol, 19 (2001), pp. 122-124
[53.]
D. Rothman, K. Smith, Y. Kimura.
Safety and efficacy of etanercept (enbrel) in children with JRA less than 4 years of age.
Arthritis Rheum, 44 (2001), pp. 1435
[54.]
H. Schmeling, K. Mathony, V. John, G. Keysser, S. Burdach, G. Horneff.
A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: A pilot study.
Ann Rheum Dis, 60 (2001), pp. 410-412
[55.]
S. Takei, D. Groh, B. Bernstein, B. Shaham, K. Gallagher, A. Reiff.
Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis.
J Rheumatol, 28 (2001), pp. 1677-1680
[56.]
D.A. Kietz, P.H. Pepmueller, T.L. Moore.
Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period.
Ann Rheum Dis, 61 (2002), pp. 171-173
[57.]
R.A. Russo, M.M. Katsicas, M. Zelazko.
Etanercept in systemic juvenile idiopathic arthritis.
Clin Exp Rheumatol, 20 (2002), pp. 723-726
[58.]
D.J. Lovell, E.H. Giannini, A. Reiff, O.Y. Jones, R. Schneider, J.C. Olson, et al.
Long-term efficacy and safety of etanercept in children with polyarticular- course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial.
Arthritis Rheum, 48 (2003), pp. 218-226
[59.]
V. Gerloni, I. Pontikaki, M. Gattinara, F. Desiati, E. Lupi, A. Lurati, et al.
Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: Results of an open-label prospective study.
Arthritis Rheum, 52 (2005), pp. 548-553
[60.]
Y. Kimura, P. Pinho, G. Walco, G. Higgins, D. Hummell, I. Szer, et al.
Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.
J Rheumatol, 32 (2005), pp. 935-942
[61.]
J. Tesser, R. Fleischmann, R. Dore, R. Bennett, A. Solinger, T. Joh, et al.
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
J Rheumatol, 31 (2004), pp. 649-654
[62.]
G. Nuki, B. Bresnihan, M.B. Bear, D. McCabe, European Group Of Clinical Investigators.
Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin- 1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial.
Arthritis Rheum, 46 (2002), pp. 2838-2846
[63.]
M. Ostergaard, A. Duer, H. Nielsen, J.S. Johansen, E. Narvestad, B.J. Ejbjerg, et al.
Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: A study of patients receiving combined anakinra and methotrexate treatment.
Ann Rheum Dis, 64 (2005), pp. 1503-1506
[64.]
R.M. Fleischmann, J. Schechtman, R. Bennett, M.L. Handel, G.R. Burmester, J. Tesser, et al.
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.
Arthritis Rheum, 48 (2003), pp. 927-934
[65.]
B. Bresnihan, R. Newmark, S. Robbins, H.K. Genant.
Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial.
J Rheumatol, 31 (2004), pp. 1103-1111
[66.]
S. Cohen, E. Hurd, J. Cush, M. Schiff, M.E. Weinblatt, L.W. Moreland, et al.
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, doubleblind, placebo-controlled trial.
Arthritis Rheum, 46 (2002), pp. 614-624
[67.]
S.B. Cohen, L.W. Moreland, J.J. Cush, M.W. Greenwald, S. Block, W.J. Shergy, et al.
A multicentre, double blind, randomised, placebo controlled trial of anakinra (kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
Ann Rheum Dis, 63 (2004), pp. 1062-1068
[68.]
J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, et al.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
N Engl J Med, 350 (2004), pp. 2572-2581
[69.]
L.W. Moreland, R. Alten, F. Van den Bosch, T. Appelboom, M. Leon, P. Emery, et al.
Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.
Arthritis Rheum, 46 (2002), pp. 1470-1479
[70.]
J.M. Kremer, M. Dougados, P. Emery, P. Durez, J. Sibilia, W. Shergy, et al.
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
Arthritis Rheum, 52 (2005), pp. 2263-2271
[71.]
J.M. Kremer, R. Westhovens, M. Leon, E. Di Giorgio, R. Alten, S. Steinfeld, et al.
Treatment of rheumatoid arthritis by selective inhibition of Tcell activation with fusion protein CTLA4Ig.
N Engl J Med, 349 (2003), pp. 1907-1915
[72.]
H. Haibel, M. Rudwaleit, J. Listing, J. Sieper.
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks.
Ann Rheum Dis, 64 (2005), pp. 296-298
[73.]
J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, W.D. Schwieterman, et al.
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
N Engl J Med, 345 (2001), pp. 1098-1104
[74.]
A. Myers, J. Clark, H. Foster.
Tuberculosis and treatment with infliximab.
N Engl J Med, 346 (2002), pp. 623-626
[75.]
Centers for Disease Control and Prevention (CDC).
Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003.
MMWR Morb Mortal Wkly Rep, 53 (2004), pp. 683-686
[76.]
A.K. Mohan, T.R. Cote, J.A. Block, A.M. Manadan, J.N. Siegel, M.M. Braun.
Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.
Clin Infect Dis, 39 (2004), pp. 295-299
[77.]
F. Wolfe, K. Michaud, J. Anderson, K. Urbansky.
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.
Arthritis Rheum, 50 (2004), pp. 372-379
[78.]
J.J. Gómez-Reino, L. Carmona, V.R. Valverde, E.M. Mola, M.D. Montero, BIOBADASER Group.
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report.
Arthritis Rheum, 48 (2003), pp. 2122-2127
[79.]
J. Askling, C.M. Fored, L. Brandt, E. Baecklund, L. Bertilsson, L. Coster, et al.
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in sweden.
Arthritis Rheum, 52 (2005), pp. 1986-1992
[80.]
D. Salmon, GTI and AFSSAPS. Groupe Tuberculose et infliximab. Agence Française de Securité Sanitaire de Produits de Santé.
Recommendations about the prevention and management of tuberculosis in patients taking infliximab.
Joint Bone Spine, 69 (2002), pp. 170-172
[81.]
D. Salmon-Ceron, Groupe Recherche Anti-TNF et Infections Opportunistes.
Agence Française de Securité Sanitaire des Produits de Santé. Recommendations for the prevention and management of tuberculosis in patients taking infliximab.
Ann Med Interne (Paris), 153 (2002), pp. 429-431
[82.]
X. Mariette, D. Salmon.
French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers.
Ann Rheum Dis, 62 (2003), pp. 791
[83.]
L. Carmona, J.J. Gómez-Reino, V. Rodríguez-Valverde, D. Montero, E. Pascual-Gómez, E.M. Mola, et al.
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Arthritis Rheum, 52 (2005), pp. 1766-1772
[84.]
P. Ormerod, H.J. Milburn, S. Gillespie, J. Ledingham, D. Rampton.
BTS recommendations for assessing risk, and for managing M. tuberculosis infection and disease, in patients due to start anti-TNF treatment.
Thorax, (2005),
[85.]
A. Keat, N. Barkham, A. Bhalla, K. Gaffney, H. Marzo-Ortega, S. Paul, et al.
BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. report of a working party of the british society for rheumatology.
Rheumatology (Oxford), 44 (2005), pp. 939-947
[86.]
S. Kyle, D. Chandler, C.E. Griffiths, P. Helliwell, J. Lewis, I. McInnes, et al.
Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
Rheumatology (Oxford), 44 (2005), pp. 390-397
[87.]
National Institute for Clinical Excelence. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. Report No.: Technology Appraisal No. 35. UK: National Institute for Clinical Excelence; 2002.
[88.]
J. Ledingham, C. Deighton, British Society for Rheumatology Standards, Guidelines and Audit Working Group.
Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of april 2001).
Rheumatology (Oxford), 44 (2005), pp. 157-163
[89.]
Panel de Expertos de la Sociedad Española de Reumatología.
Primer documento de consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNF-α en las espondiloartritis.
Reumatol Clin, 1 (2005), pp. 32-37
[90.]
T. Takeuchi.
Guidelines for usage of biological agents for treatment of rheumatoid arthritis.
Nippon Rinsho, 63 (2005), pp. 444-447
[91.]
C. Salvarani, I. Olivieri, F. Cantini, A. Marchesoni, L. Punzi, R. Scarpa, et al.
Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. italian rheumatology society.
Reumatismo, 56 (2004), pp. 133-134
[92.]
N.J. Bansback, A. Young, A. Brennan.
The NICE reappraisal of biologics in 2005: What rheumatologists need to know.
Rheumatology (Oxford), 44 (2005), pp. 3-4
[93.]
J. Braun, T. Pham, J. Sieper, J. Davis, S. Van der Linden, M. Dougados, et al.
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.
Ann Rheum Dis, 62 (2003), pp. 817-824
[94.]
W.P. Maksymowych, R.D. Inman, D. Gladman, G. Thomson, M. Stone, J. Karsh, et al.
Canadian rheumatology association consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
J Rheumatol, 30 (2003), pp. 1356-1363
[95.]
I. Olivieri, C. Salvarani, F. Cantini, L. Punzi, M. Matucci Cerinic.
Recommendations for starting anti TNF-alpha in patients with ankylosing spondylitis.
Reumatismo, 55 (2003), pp. 220-223
[96.]
Recommendations of the German Society of Rheumatology for therapy with tumor necrosis factor inhibitors.
pharmacotherapy committee of the German society of rheumatology.
Z Rheumatol, 59 (2000), pp. 291-292
[97.]
J. Braun, J. Davis, M. Dougados, J. Sieper, S. Van der Linden, D. Van der Heijde.
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.
Ann Rheum Dis, (2005),
[98.]
E. Díaz-Jouanen, C. Abud-Mendoza, M.A. Garza-Elizondo, G. Medrano-Ramírez, J. Orozco-Alcalá, C. Pacheco-Tena, et al.
Recomendaciones para el tratamiento médico de la artritis reumatoide.
Rev Inv Clin, 57 (2005), pp. 735-755
[99.]
F.C. Arnett, S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper, et al.
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Arthritis Rheum, 31 (1988), pp. 315-324
[100.]
S. Van der Linden, H.A. Valkenburg, A. Cats.
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.
Arthritis Rheum, 27 (1984), pp. 361-368
[101.]
J.M. Moll, V. Wright.
Psoriatic arthritis.
Semin Arthritis Rheum, 3 (1973), pp. 55-78
[102.]
R.E. Petty, T.R. Southwood, P. Manners, J. Baum, D.N. Glass, J. Goldenberg, et al.
International League of Associations for Rheumatology Classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001.
J Rheumatol, 31 (2004), pp. 390-392
[103.]
R.E. Petty, T.R. Southwood, J. Baum, E. Bhettay, D.N. Glass, P. Manners, et al.
Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997.
J Rheumatol, 25 (1998), pp. 1991-1994
[104.]
E.M. Tan, A.S. Cohen, J.F. Fries, A.T. Masi, D.J. McShane, N.F. Rothfield, et al.
The 1982 revised criteria for the classification of systemic lupus erythematosus.
Arthritis Rheum, 25 (1982), pp. 1271-1277

* Correspondencia: Dr. R. Burgos-Vargas. Hospital General de México. Dr. Balmis 148. México DF 06726. México. burgosv@attglobal.net y burgosv@prodigy.net.mx.

Copyright © 2006. Elsevier España S.L Barcelona
Idiomas
Reumatología Clínica
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?